Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Molecular Cancer
Published in: Molecular Cancer 1/2005

Open Access 01-12-2005 | Review

Epigenetics of cervical cancer. An overview and therapeutic perspectives

Authors: Alfonso Dueñas-González, Marcela Lizano, Myrna Candelaria, Lucely Cetina, Claudia Arce, Eduardo Cervera

Published in: Molecular Cancer | Issue 1/2005

Login to get access

Abstract

Cervical cancer remains one of the greatest killers of women worldwide. It is difficult to foresee a dramatic increase in cure rate even with the most optimal combination of cytotoxic drugs, surgery, and radiation; therefore, testing of molecular targeted therapies against this malignancy is highly desirable. A number of epigenetic alterations occur during all stages of cervical carcinogenesis in both human papillomavirus and host cellular genomes, which include global DNA hypomethylation, hypermetylation of key tumor suppressor genes, and histone modifications. The reversible nature of epigenetic changes constitutes a target for transcriptional therapies, namely DNA methylation and histone deacetylase inhibitors. To date, studies in patients with cervical cancer have demonstrated the feasibility of reactivating the expression of hypermethylated and silenced tumor suppressor genes as well as the hyperacetylating and inhibitory effect upon histone deacetylase activity in tumor tissues after treatment with demethylating and histone deacetylase inhibitors. In addition, detection of epigenetic changes in cytological smears, serum DNA, and peripheral blood are of potential interest for development of novel biomolecular markers for early detection, prediction of response, and prognosis.
Literature
1.
Parkin DM, Bray F, Ferlay J, Pisani P: Estimating the world cancer burden: Globocan 2000. Int J Cancer. 2001, 94: 153-156. 10.1002/ijc.1440.PubMedCrossRef
2.
Richart RM, Barron BA: A follow-up study of patients with cervical displasia. Am J Obstet Gynecol. 1969, 105: 386-371.PubMed
3.
Dueñas-Gonzalez A, Cetina L, Mariscal I, de la Garza J: Modern management of locally advanced cervical carcinoma. Cancer Treat Rev. 2003, 29: 389-399. 10.1016/S0305-7372(03)00068-9.PubMedCrossRef
4.
Whitney CW, Sause W, Bundy BN, Malfetano JH, Hannigan EV, Fowler WC, Clarke-Pearson DL, Liao SY: A randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stages IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes. A Gynecologic Oncology Group and Southwest Oncology Group Study. J Clin Oncol. 1999, 17: 1339-1348.PubMed
5.
Sedlis A, Bundy BN, Rotman MZ, Lentz SS, Muderspach LI, Zaino RJ: A randomized trial of pelvic radiation therapy versus no further therapy in selected patients with stage IB carcinoma of the cervix after radical hysterectomy and pelvic lymphadenectomy: A Gynecologic Oncology Group Study. Gynecol Oncol. 1999, 73: 177-183. 10.1006/gyno.1999.5387.PubMedCrossRef
6.
Annual Report on the Results of Treatment in Gynaecological Cancer. J Epidemiol Statist. 1998, 3: 5-34.
7.
Brunschwig A, Daniel W: Evaluation of pelvic exenteration for advanced cancer of the cervix. Surg Gynecol Obstet. 1956, 103: 337-341.PubMed
8.
Green JA, Kirwan JM, Tierney JF: Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix: a systematic review and meta-analysis. Lancet. 2001, 358: 781-786. 10.1016/S0140-6736(01)05965-7.PubMedCrossRef
9.
Neoadjuvant Chemotherapy for Locally Advanced Cervical Cancer Meta-analysis Collaboration: Neoadjuvant chemotherapy for locally advanced cervical cancer: a systematic review and meta-analysis of individual patient data from 21 randomised trials. Eur J Cancer. 2003, 39: 2470-2486. 10.1016/S0959-8049(03)00425-8.CrossRef
10.
López MJ, Spratt JS: Exenterative pelvic surgery. J Surg Oncol. 1999, 72: 102-114. 10.1002/(SICI)1096-9098(199910)72:2<102::AID-JSO12>3.0.CO;2-1.PubMedCrossRef
11.
Hockel M, Knapstein P: The combined operative and radiotherapeutic treatment of recurrent tumors infiltrating the pelvic wall. Gynecol Oncol. 1992, 46: 20-28. 10.1016/0090-8258(92)90189-P.PubMedCrossRef
12.
Maneo A, Landoni F, Cormio G, Colombo A, Placa F, Pellegrino A, Mangioni C: Concurrent carboplatin/5-fluorouracil and radiotherapy for recurrent cervical carcinoma. Ann Oncol. 1999, 10: 803-807. 10.1023/A:1008356010556.PubMedCrossRef
13.
Friedlander M: Guidelines for the treatment of recurrent and metastatic cervical cancer. Oncologist. 2002, 7: 342-347.PubMed
14.
Gemignani ML, Alektiar KM, Leitao M, Mychalczak B, Chi D, Venkatraman E, Barakat RR, Curtin JP: Radical surgical resection and high-dose intraoperative radiation therapy (HDR-IORT) in patients with recurrent gynecologic cancers. Int J Radiat Oncol Biol Phys. 2001, 50: 687-694. 10.1016/S0360-3016(01)01507-3.PubMedCrossRef
15.
Hockel M: Laterally extended endopelvic resection: surgical treatment of infrailiac pelvic wall recurrences of gynecological malignancies. Am J Obstet Gynecol. 1999, 180: 306-312.PubMedCrossRef
16.
López-Graniel C, Dolores-Velázquez R, Cetina L, González-Enciso A, Chanona J, Uribe-Domínguez J, Candelaria M, de la Garza J, Dueñas-González A: Pre-exenterative chemotherapy for patients with recurrent cervical cancer patients who do not met the classical criteria for pelvic exenteration. A novel therapeutic approach. BMC Cancer.
17.
Bonomi P, Blessing JA, Stehman FB, DiSaia PJ, Walton L, Major FJ: Randomized trial of three cisplatin dose schedules in squamous-cell carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol. 1985, 3: 1079-1085.PubMed
18.
Long HJ, Bundy BN, Grendys EC, Benda JA, McMeekin DS, Sorosky J, Miller DS, Eaton LA, Fiorica JV: Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: A Gynecologic Oncology Group study. J Clin Oncol. 2005, 21: 4626-4633. 10.1200/JCO.2005.10.021.CrossRef
19.
zur Hausen: Papillomaviruses in human cancers. Proc Assoc Am Physicians. 1999, 111: 581-587. 10.1046/j.1525-1381.1999.99723.x.CrossRef
20.
Muñoz N, Bosch FX, de Sanjosé S, Herrero R, Castellsague X, Shah KV, Snijders PJ, Meijer CJ: International Agency for Research on Cancer Multicenter Cervical Cancer Study Group. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003, 348: 518-527. 10.1056/NEJMoa021641.PubMedCrossRef
21.
Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Muñoz N: Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999, 189: 12-19. 10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F.PubMedCrossRef
22.
Baker CC, Phelps WC, Lindgren V, Braun MJ, Gonda MA, Howley PM: Structural and transcriptional analysis of human papillomavirus type 16 sequences in cervical carcinoma cell lines. J Virol. 1987, 61: 962-967.PubMedCentralPubMed
23.
Ward P, Coleman DV, Malcolm DB: Regulatory mechanisms of the papillomavirus. Trends Genet. 1989, 5: 97-99. 10.1016/0168-9525(89)90037-1.PubMedCrossRef
24.
Thierry F, Benotmane MA, Demeret C, Mori M, Teissier S, Desaintes O: A genomic approach reveals a novel mitotic pathway in papillomavirus carcinogenesis. Cancer Res. 2004, 64: 895-903. 10.1158/0008-5472.CAN-03-2349.PubMedCrossRef
25.
Stubenrauch F, Laimins LA: Human papillomavirus life cycle: active and latent phases. Semin Cancer Biol. 1999, 9: 379-386. 10.1006/scbi.1999.0141.PubMedCrossRef
26.
Stubenrauch F, Zoble T, Iftner T: The E8 domain confers a novel long-distance transcriptional repression activity on the E8E2Cprotein of high-risk human papillomavirus type 31. J Virol. 2001, 75: 4139-4149. 10.1128/JVI.75.9.4139-4149.2001.PubMedCentralPubMedCrossRef
27.
Brown DF, Fan L, Jones J, Bryan J: Colocalization of human papillomavirus type 11 E1 E4 and L1 proteins in human foreskin implants grown in athymic mice. Virology. 1994, 201: 46-54. 10.1006/viro.1994.1264.PubMedCrossRef
28.
Crucius K, Auvinen E, Alonso A: Enhancement of EGF and PMA-mediated MAP kinase activation in cells expressing the human papillomavirus type 16 E5 protein. Oncogene. 1997, 15: 1437-1444. 10.1038/sj.onc.1201312.CrossRef
29.
Munger K, Howley PM: Human papillomavirus immortalization and transformation functions. Virus Res. 2002, 89: 213-228. 10.1016/S0168-1702(02)00190-9.PubMedCrossRef
30.
Howley PM, Scheffner M, Munger K: Oncoproteins encoded by the cancer-associated papillomavirus target the products of retinoblastoma and p53 tumor suppressor genes. Quant Biol. 1991, 56: 159-155.CrossRef
31.
Henstermann A, Linares LK, Ciechanover A: Complete switch form Mdm2 to human papillomavirus E6-mediated degradation of p53 in cervical cancer cells. Proc Natl Acad Sci USA. 2001, 98: 1218-1223. 10.1073/pnas.031470698.CrossRef
32.
Mantovani F, Banks L: The human papillomavirus E6 protein and its contribution to malignant progression. Oncogene. 2001, 20: 7874-7887. 10.1038/sj.onc.1204869.PubMedCrossRef
33.
Werness BA, Levine AJ, Howley PM: Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science. 1990, 248: 76-79.PubMedCrossRef
34.
Di Leonardo A, Linke SP, Clarkin K, Wahl GM: DNA damage triggers a prolonged p53-dependent G1 arrest and long-term induction of Cip1 in normal human fibroblasts. Genes Dev. 1994, 8: 2540-2551.PubMedCrossRef
35.
Smith ML, Chen IT, Zhan Q, O'Connor PM, Fornace AJ: Involvement of the p53 tumor suppressor in repair of u.v.-type DNA damage. Oncogene. 1995, 10: 1053-1059.PubMed
36.
Hwang ES, Riese DJ, Settleman J, Nilson LA, Honig J, Flynn S, DiMaio D: Inhibition of cervical carcinoma cell line proliferation by the introduction of a bovine papillomavirus regulatory gene. Virology. 1993, 67: 3720-3729.
37.
Southern SA, Herrington CS: Disruption of cell cycle control by human papillomavirus with special reference to cervical carcinoma. Int J Gynecol Cancer. 2000, 10: 263-274. 10.1046/j.1525-1438.2000.010004263.x.PubMedCrossRef
38.
Doorbar J, Ely S, Sterling J, McLean C, Crawford L: Specific interaction between HPV16 E1–E4 and cytokeratins results in collapse of the epithelial cell intermediate filament network. Nature. 1991, 352: 824-827. 10.1038/352824a0.PubMedCrossRef
39.
Ueda Y, Enomoto T, Miyatake T, Ozaki K, Yoshizaki T, Kanao H, Ueno Y, Nakashima R, Shroyer KR, Murata Y: Monoclonal expansion with integration of high-risk type human papillomavirus is an essential step for cervical carcinogenesis: association of clonal status and human papillomavirus infection with clinical outcome in cervical intraepithelial neoplasia. Lab Invest. 2003, 83: 1517-1527. 10.1097/01.LAB.0000092234.68751.83.PubMedCrossRef
40.
41.
Egger G, Liang G, Aparicio A, Jones PA: Epigenetics in human disease and prospects for epigenetic therapy. Nature. 2004, 429: 457-463. 10.1038/nature02625.PubMedCrossRef
42.
Kawasaki H, Taira K: Transcriptional gene silencing by short interfering RNAs. Curr Opin Mol Ther. 2005, 7: 125-131.PubMed
43.
Colot V, Rossignol JL: Eukaryotic DNA methylation as an evolutionary device. Bioessays. 1999, 21: 402-411. 10.1002/(SICI)1521-1878(199905)21:5<402::AID-BIES7>3.0.CO;2-B.PubMedCrossRef
44.
45.
Bird AP: CpG-rich islands and the function of DNA methylation. Nature. 1986, 321: 209-213. 10.1038/321209a0.PubMedCrossRef
46.
47.
Robert MF, Morin S, Beaulieu N, Gauthier F, Chute IC, Barsalou A, MacLeod AR: DNMT1 is required to maintain CpG methylation and aberrant gene silencing in human cancer cells. Nat Genet. 2003, 33: 61-65. 10.1038/ng1068.PubMedCrossRef
48.
Wang KY, James-Shen CK: DNA methyltransferase Dnmt1 and mismatch repair. Oncogene. 2004, 23: 7898-7902. 10.1038/sj.onc.1208111.PubMedCrossRef
49.
Okano M, Bell DW, Haber DA, Li E: DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. Cell. 1999, 99: 247-257. 10.1016/S0092-8674(00)81656-6.PubMedCrossRef
50.
Liu K, Wang YF, Cantemir C, Muller MT: Endogenous assays of DNA methyltransferases: evidence for differential activities of DNMT1, DNMT2, and DNMT3 in mammalian cells in vivo. Mol Cell Biol. 2003, 23: 2709-2719. 10.1128/MCB.23.8.2709-2719.2003.PubMedCentralPubMedCrossRef
51.
Reik W, Dean W, Walter J: Epigenetic reprogramming in mammalian development. Science. 2001, 293: 1089-1093. 10.1126/science.1063443.PubMedCrossRef
52.
Zhu WG, Srinivasan K, Dai Z, Duan W, Druhan LJ, Ding H, Yee L, Villalona-Calero MA, Plass C, Otterson GA: Methylation of adjacent CpG sites affects Sp1/Sp3 binding and activity in the p21(Cip1) promoter. Mol Cell Biol. 2003, 23: 4056-4065. 10.1128/MCB.23.12.4056-4065.2003.PubMedCentralPubMedCrossRef
53.
Nguyen CT, Gonzales FA, Jones PA: Altered chromatin structure associated with methylation-induced gene silencing in cancer cells: correlation of accessibility, methylation, MeCP2 binding and acetylation. Nucleic Acids Res. 2001, 29: 4598-4606. 10.1093/nar/29.22.4598.PubMedCentralPubMedCrossRef
54.
Geiman TM, Robertson KD: Chromatin remodeling, histone modifications, and DNA methylation- how does it all fit together?. Cell Biochem. 2002, 87: 117-125. 10.1002/jcb.10286.CrossRef
55.
Baylin SB: Reversal of gene silencing as a therapeutic target for cancer- roles for DNA methylation and its interdigitation with chromatin. Novartis Found Symp. 2004, 259: 226-233.PubMedCrossRef
56.
Bird A: 2002 DNA methylation patterns and epigenetic memory. Genes Dev. 2000, 16: 6-21. 10.1101/gad.947102.CrossRef
57.
Chakravarthy S, Park YJ, Chodaparambil J, Edayathumangalam RS, Luger K: Structure and dynamic properties of nucleosome core particles. FEBS Lett. 2005, 579: 895-898. 10.1016/j.febslet.2004.11.030.PubMedCrossRef
58.
Kuo MH, Allis CD: Roles of histone acetyltransferases and deacetylases in gene regulation. Bioessays. 1998, 20: 615-626. 10.1002/(SICI)1521-1878(199808)20:8<615::AID-BIES4>3.0.CO;2-H.PubMedCrossRef
59.
Wang C, Fu M, Mani S, Wadler S, Senderowicz AM, Pestell RG: Histone acetylation and the cell-cycle in cancer. Front Biosci. 2001, 6: D610-D629.PubMedCrossRef
60.
Davie JR: Covalent modifications of histones: expression from chromatin templates. Curr Opin Genet Dev. 1998, 8: 173-178. 10.1016/S0959-437X(98)80138-X.PubMedCrossRef
61.
Trievel RC: Structure and function of histone methyltransferases. Crit Rev Eukaryot Gene Expr. 2004, 14: 147-169. 10.1615/CritRevEukaryotGeneExpr.v14.i3.10.PubMedCrossRef
62.
Daniel JA, Pray-Grant MG, Grant PA: Effector proteins for methylated histones: an expanding family. Cell Cycle. 2005, .
63.
Lachner M, O'Carroll D, Rea S, Mechtler K, Jenuwein T: Methylation of histone H3 lysine 9 creates a binding site for HP1 proteins. Nature. 2001, 410: 116-120. 10.1038/35065132.PubMedCrossRef
64.
Mahadevan LC, Willis AC, Barratt MJ: Rapid histone H3 phosphorylation in response to growth factors, phorbol esters, okadaic acid, and protein synthesis inhibitors. Cell. 1991, 65: 775-783. 10.1016/0092-8674(91)90385-C.PubMedCrossRef
65.
66.
Pascreau G, Arlot-Bonnemains Y, Prigent C: Phosphorylation of histone and histone-like proteins by aurora kinases during mitosis. Prog Cell Cycle Res. 2003, 5: 369-374.PubMed
67.
Agalioti T, Chen G, Thanos D: Deciphering the transcriptional histone acetylation code for a human gene. Cell. 2002, 111: 381-392. 10.1016/S0092-8674(02)01077-2.PubMedCrossRef
68.
de la Cruz X, Lois S, Sánchez-Molina S, Martínez-Balbas MA: Do protein motifs read the histone code?. Bioessays. 2005, 27: 164-175. 10.1002/bies.20176.PubMedCrossRef
69.
Feinberg AP, Vogelstein B: Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature. 1983, 301: 89-92. 10.1038/301089a0.PubMedCrossRef
70.
de Bustros A, Nelkin BD, Silverman A, Ehrlich G, Poiesz B, Baylin SB: The short arm of chromosome 11 is a "hot spot" for hypermethylation in human neoplasia. Proc Natl Acad Sci U S A. 1988, 85: 5693-5697.PubMedCentralPubMedCrossRef
71.
Laird PW, Jaenisch R: DNA methylation and cancer. Hum Molec Genet. 1994, 3: 1487-1495.PubMed
72.
Greger V, Passarge E, Hopping W, Messmer E, Horsthemke B: Epigenetic changes may contribute to the formation and spontaneous regression of retinoblastoma. Hum Genet. 1989, 83: 155-158. 10.1007/BF00286709.PubMedCrossRef
73.
Santini V, Kantarjian HM, Issa JP: Changes in DNA methylation in neoplasia: pathophysiology and therapeutic implications. Ann Intern Med. 2001, 134: 573-586.PubMedCrossRef
74.
Szyf M, Targeti NG: DNA methylation in cancer. Ageing Res Rev. 2003, 2: 299-328. 10.1016/S1568-1637(03)00012-6.PubMedCrossRef
75.
Bachman KE: Histone modifications and silencing prior to DNA methylation of a tumor suppressor gene. Cancer Cell. 2003, 3: 89-95. 10.1016/S1535-6108(02)00234-9.PubMedCrossRef
76.
Clark SJ, Melki J: DNA methylation and gene silencing in cancer: which is the guilty part?. Oncogene. 2002, 21: 5380-5387. 10.1038/sj.onc.1205598.PubMedCrossRef
77.
Goelz SE, Vogelstein B, Hamilton SR, Feinberg AP: Hypomethylation of DNA from benign and malignant human colon neoplasms. Science. 1985, 228: 187-190.PubMedCrossRef
78.
Feinberg AP, Gehrke CW, Kuo KC, Ehrlich M: Reduced genomic 5-methylcytosine content in human colonic neoplasia. Cancer Res. 1988, 48: 1159-1161.PubMed
79.
Ehrlich M: DNA hypomethylation, cancer, the immunodeficiency, centromeric region instability, facial anomalies syndrome and chromosomal rearrangements. J Nutr. 2002, 132: 2424S-2429S.PubMed
80.
81.
Gamma-Sosa MA, Slagel VA, Trewyn RW, Oxenhandler R, Kuo KC, Gehrke CW, Ehrlich M: The 5-methylcytosine content of DNA from human tumors. Nucleic Acids Res. 1983, 11: 6883-6894.CrossRef
82.
Eden A, Gaudet F, Waghmare A, Jaenisch R: Chromosomal instability and tumors promoted by DNA hypomethylation. Science. 2003, 300: 455-10.1126/science.1083557. 10.1126/science.1083557PubMedCrossRef
83.
Hansen RS, Wijmenga C, Luo P, Stanek AM, Canfield TK, Weemaes CM, Gartler SM: The DNMT3B DNA methyltransferase gene is mutated in the ICF immunodeficiency syndrome. Proc Natl Acad Sci U S A. 1999, 96: 14412-14417. 10.1073/pnas.96.25.14412.PubMedCentralPubMedCrossRef
84.
Narayan A, Ji W, Zhang XY, Marrogi A, Graff JR, Baylin SB, Ehrlich M: Hypomethylation of pericentromeric DNA in breast adenocarcinomas. Int J Cancer. 1998, 77: 833-838. 10.1002/(SICI)1097-0215(19980911)77:6<833::AID-IJC6>3.0.CO;2-V.PubMedCrossRef
85.
Strichman-Almashanu LZ: A genome-wide screen for normally methylated human CgG islands that can identify novel imprinted genes. Genome Res. 2002, 12: 543-554. 10.1101/gr.224102. Article published online before print in March 2002.PubMedCentralPubMedCrossRef
86.
Ogishima T, Shiina H, Breault JE, Tabatabai L, Bassett WW, Enokida H, Li LC, Kawakami T, Urakami S, Ribeiro-Filho LA, Terashima M, Fujime M, Igawa M, Dahiya R: Increased heparanase expression is caused by promoter hypomethylation and up-regulation of transcriptional factor early growth response-1 in human prostate cancer. Clin Cancer Res. 2005, 11: 1028-1036.PubMed
87.
Sato N, Maitra A, Fukushima N, Van Heek NT, Matsubayashi H, Iacobuzio-Donahue CA, Rosty C, Goggins M: Frequent hypomethylation of multiple genes overexpressed in pancreatic ductal adenocarcinoma. Cancer Res. 2003, 63: 4158-4166.PubMed
88.
Akiyama Y, Maesawa C, Ogasawara S, Terashima M, Masuda T: Cell-type-specific repression of the maspin gene is disrupted frequently by demethylation at the promoter region in gastric intestinal metaplasia and cancer cells. Am J Pathol. 2003, 163: 1911-1919.PubMedCentralPubMedCrossRef
89.
Karpf AR, Lasek AW, Ririe TO, Hanks AN, Grossman D, Jones DA: Limited gene activation in tumor and normal epithelial cells treated with the DNA methyltransferase inhibitor 5-aza-2'-deoxycytidine. Mol Pharmacol. 2004, 65: 18-27. 10.1124/mol.65.1.18.PubMedCrossRef
90.
Koshiishi N, Chong JM, Fukasawa T, Ikeno R, Hayashi Y, Funata N, Nagai H, Miyaki M, Matsumoto Y, Fukayama M: p300 Gene alterations in intestinal and diffuse types of gastric carcinoma. Gastric Cancer. 2004, 7: 85-90. 10.1007/s10120-004-0273-8.PubMedCrossRef
91.
Ward R, Johnson M, Shridhar V, van Deursen J, Couch FJ: CBP truncating mutations in ovarian cancer. J Med Genet. 2005, 42: 514-518. 10.1136/jmg.2004.025080.PubMedCentralPubMedCrossRef
92.
So CK, Nie Y, Song Y: Loss of heterozygosity and internal tandem duplication mutations of the CBP gene are frequent events in human esophageal squamous cell carcinoma. Clin Cancer Res. 2004, 10: 19-27. 10.1158/1078-0432.CCR-03-0160.PubMedCrossRef
93.
Kishimoto M, Kohno T, Okudela K, Otsuka A, Sasaki H, Tanabe C, Sakiyama T, Hirama C, Kitabayashi I, Minna JD, Takenoshita S, Yokota J: Mutations and deletions of the CBP gene in human lung cancer. Clin Cancer Res. 2005, 11: 512-519.PubMed
94.
Sobulo OM, Borrow J, Tomek R, Reshmi S, Harden A, Schlegelberger B, Housman D, Doggett NA, Rowley JD, Zeleznik-Le NJ: MLL is fused to CBP, a histone acetyltransferase, in therapy-related acute myeloid leukemia with a t(11;16)(q23;p13.3). Proc Natl Acad Sci U S A. 1997, 94: 8732-8777. 10.1073/pnas.94.16.8732.PubMedCentralPubMedCrossRef
95.
Chaffanet M, Gressin L, Preudhomme C, Soenen-Cornu V, Birnbaum D, Pebusque MJ: MOZ is fused to p300 in an acute monocytic leukemia with t(8;22). Genes Chromosomes Cancer. 2000, 28: 138-144. 10.1002/(SICI)1098-2264(200006)28:2<138::AID-GCC2>3.0.CO;2-2.PubMedCrossRef
96.
Lin RJ, Nagy L, Inoue S, Shao W, Miller WH, Evans RM: Role of the histone deacetylase complex in acute promyelocytic leukaemia. Nature. 1998, 391: 811-814. 10.1038/35895.PubMedCrossRef
97.
Licht JD: AML1 and the AML1-ETO fusion protein in the pathogenesis of t(8;21) AML. Oncogene. 2001, 20: 5660-5679. 10.1038/sj.onc.1204593.PubMedCrossRef
98.
Melnick A, Carlile G, Ahmad KF, Kiang CL, Corcoran C, Bardwell V, Prive GG, Licht JD: Critical residues within the BTB domain of PLZF and Bcl-6 modulate interaction with corepressors. Mol Cell Biol. 2002, 22: 1804-1818. 10.1128/MCB.22.6.1804-1818.2002.PubMedCentralPubMedCrossRef
99.
100.
Tao Q, Huang H, Geiman TM, Lim CY, Fu L, Qiu GH, Robertson KD: Defective de novo methylation of viral and cellular DNA sequences in ICF syndrome cells. Hum Mol Genet. 2002, 11: 2091-2102. 10.1093/hmg/11.18.2091.PubMedCrossRef
101.
Tao Q, Robertson KD: Stealth technology: how Epstein-Barr virus utilizes DNA methylation to cloak itself from immune detection. Clin Immunol. 2003, 109: 53-63. 10.1016/S1521-6616(03)00198-0.PubMedCrossRef
102.
Tsai CN, Tsai CL, Tse KP, Chang HY, Chang YS: The Epstein-Barr virus oncogene product, latent membrane protein 1, induces the downregulation of E-cadherin gene expression via activation of DNA methyltransferases. Proc Natl Acad Sci U S A. 2002, 99: 10084-10089. 10.1073/pnas.152059399.PubMedCentralPubMedCrossRef
103.
Rosl F, Arab A, Klevenz B, zur Hausen H: The effect of DNA methylation on gene regulation of human papillomaviruses. J Gen Virol. 1993, 74: 791-801.PubMedCrossRef
104.
Badal V, Chuang LS, Tan EH, Badal S, Villa LL, Wheeler CM, Li BF, Bernard HU: CpG methylation of human papillomavirus type 16 DNA in cervical cancer cell lines and in clinical specimens: genomic hypomethylation correlates with carcinogenic progression. Virology. 2003, 77: 6227-6234. 10.1128/JVI.77.11.6227-6234.2003.CrossRef
105.
Kalantari M, Calleja-Macías IE, Tewari D, Hagmar B, Lie K, Barrera-Saldaña HA, Wiley DJ, Bernard HU: Conserved methylation patterns of human papillomavirus type 16 DNA in asymptomatic infection and cervical neoplasia. J Virol. 2004, 78: 12762-12772. 10.1128/JVI.78.23.12762-12772.2004.PubMedCentralPubMedCrossRef
106.
Badal S, Badal V, Calleja-Macías IE, Kalantari M, Chuang LS, Li BF, Bernard HU: The human papillomavirus-18 genome is efficiently targeted by cellular DNA methylation. Virology. 2004, 324: 483-492. 10.1016/j.virol.2004.04.002.PubMedCrossRef
107.
Thain A, Jenkins O, Clarke AR, Gaston K: CpG methylation directly inhibits binding of the human papillomavirus type 16 E2 protein to specific DNA sequences. J Virol. 1996, 70: 7233-7235.PubMedCentralPubMed
108.
Kim K, Garner-Hamrick PA, Fisher C, Lee D, Lambert PF: Methylation patterns of papillomavirus DNA, its influence on E2 function, and implications in viral infection. J Virol. 2003, 77: 12450-12459. 10.1128/JVI.77.23.12450-12459.2003.PubMedCentralPubMedCrossRef
109.
Soengas MS, Capodieci P, Polsky D, Mora J, Esteller M, Opitz-Araya X, McCombie R, Herman JG, Gerald WL, Lazebnik YA, Cordon-Cardo C, Lowe SW: Inactivation of the apoptosis effector Apaf-1 in malignant melanoma. Nature. 2001, 409: 207-211. 10.1038/35051606.PubMedCrossRef
110.
van Noesel MM, van Bezouw S, Salomons GS, Voute PA, Pieters R, Baylin SB, Herman JG, Versteeg R: Tumor-specific down-regulation of the tumor necrosis factor-related apoptosis-inducing ligand decoy receptors DcR1 and DcR2 is associated with dense promoter hypermethylation. Cancer Res. 2002, 62: 2157-2161.PubMed
111.
Ashkenazi A, Dixit VM: Apoptosis control by death and decoy receptors. Curr Opin Cell Biol. 1999, 11: 255-260. 10.1016/S0955-0674(99)80034-9.PubMedCrossRef
112.
Ozoren N, El-Deiry WS: Cell surface death receptor signaling in normal and cancer cells. Semin Cancer Biol. 2003, 13: 135-147. 10.1016/S1044-579X(02)00131-1.PubMedCrossRef
113.
Shivapurkar N, Toyooka S, Toyooka KO, Reddy J, Miyajima K, Suzuki M, Shigematsu H, Takahashi T, Parikh G, Pass HI, Chaudhary PM, Gazdar AF: Aberrant methylation of trail decoy receptor genes is frequent in multiple tumor types. Int J Cancer. 2004, 109: 786-792. 10.1002/ijc.20041.PubMedCrossRef
114.
Weinrich SL, Pruzan R, Ma L, Ouellette M, Tesmer VM, Holt SE: Reconstitution of human telomerase with the template RNA component hTR and the catalytic protein subunit hTRT. Nature Genet. 1997, 17: 498-502. 10.1038/ng1297-498.PubMedCrossRef
115.
116.
Yokoyama Y, Takahashi Y, Shinohara A, Lian Z, Tamaya T: Telomerase activity in the female reproductive tract and neoplasms. Gynecol Oncol. 1998, 68: 145-149. 10.1006/gyno.1997.4921.PubMedCrossRef
117.
Nakano N, Watney E, McDougall JK: Telomerase activity and expression of telomerase RNA component and telomerase catalytic subunit gene in cervical cancer. Am J Pathol. 1998, 153: 857-864.PubMedCentralPubMedCrossRef
118.
Snijders PJ, van Duin M, Walboomers JM, Steenbergen RD, Risse EK, Helmerhorst TJ: Telomerase activity exclusively in cervical carcinomas and a subset of cervical intraepithelial neoplasia grade III lesions: strong association with elevated messenger RNA levels of its catalytic subunit and high-risk human papillomavirus DNA. Cancer Res. 1998, 58: 3812-3818.PubMed
119.
Takakura M, Kyo S, Kanaya T, Tanaka M, Inoue M: Expression of human telomerase subunits and correlation with telomerase activity in cervical cancer. Cancer Res. 1998, 58: 1558-1561.PubMed
120.
Wisman GB, Knol AJ, Helder MN, Krans M, Vries EG, Hollema H: Telomerase in relation to clinicopathologic prognostic factors and survival in cervical cancer. Int J Cancer. 2001, 91: 658-664. 10.1002/1097-0215(200002)9999:9999<::AID-IJC1099>3.0.CO;2-7.PubMedCrossRef
121.
Guilleret I, Benhattar J: Demethylation of the human telomerase catalytic subunit (hTERT) gene promoter reduced hTERT expression and telomerase activity and shortened telomeres. Exp Cell Res. 2003, 289: 326-334. 10.1016/S0014-4827(03)00281-7.PubMedCrossRef
122.
Widschwendter A, Muller HM, Hubalek MM, Wiedemair A, Fiegl H, Goebel G, Mueller-Holzner E, Marth C, Widschwendter M: Methylation status and expression of human telomerase reverse transcriptase in ovarian and cervical cancer. Gynecol Oncol. 2004, 93: 407-416. 10.1016/j.ygyno.2004.01.036.PubMedCrossRef
123.
124.
Harris SL, Levine AJ: The p53 pathway: positive and negative feedback loops. Oncogene. 2005, 24: 2899-2908. 10.1038/sj.onc.1208615.PubMedCrossRef
125.
Melino G, De Laurenzi V, Vousden KH: p73: friend or foe in tumorigenesis. Nature Rev Cancer. 2002, 2: 605-615. 10.1038/nrc861.CrossRef
126.
Zhu J, Jiang J, Zhou W, Chen X: The potential tumor suppressor p73 differentially regulates cellular p53 target genes. Cancer Res. 1998, 58: 5061-5065.PubMed
127.
Yang A, Kaghad M, Wang Y: p63, A p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. Molec Cell. 1998, 2: 305-316. 10.1016/S1097-2765(00)80275-0.PubMedCrossRef
128.
Banelli B, Casciano I, Romani M: Methylation-independent silencing of the p73 gene in neuroblastoma. Oncogene. 2000, 19: 4553-4556. 10.1038/sj.onc.1203807.PubMedCrossRef
129.
Liu SS, Leung RC, Chan KY, Chiu PM, Cheung AN, Tam KF, Ng TY, Wong LC, Ngan HY: p73 Expression is associated with the cellular radiosensitivity in cervical cancer after radiotherapy. Clin Cancer Res. 2004, 10: 3309-3316. 10.1158/1078-0432.CCR-03-0119.PubMedCrossRef
130.
Nakashima R, Fujita M, Enomoto T, Haba T, Yoshino K, Wada H, Kurachi H, Sasaki M, Wakasa K, Inoue M, Buzard G, Murata Y: Alteration of p16 and p15 genes in human uterine tumours. Br J Cancer. 1999, 80: 458-467. 10.1038/sj.bjc.6690379.PubMedCentralPubMedCrossRef
131.
Nuovo GJ, Plaia TW, Belinsky SA, Baylin SB, Herman JG: In situ detection of the hypermethylation-induced inactivation of the p16 gene as an early event in oncogenesis. Proc Natl Acad Sci U S A. 1999, 96: 12754-12759. 10.1073/pnas.96.22.12754.PubMedCentralPubMedCrossRef
132.
Wong YF, Chung TK, Cheung TH, Nobori T, Yu AL, Yu J, Batova A, Lai KW, Chang AM: Methylation of p16INK4A in primary gynecologic malignancy. Cancer Lett. 1999, 136: 231-235. 10.1016/S0304-3835(98)00327-9.PubMedCrossRef
133.
Narayan G, Arias-Pulido H, Koul S, Vargas H, Zhang FF, Villella J, Schneider A, Terry MB, Mansukhani M, Murty VV: Frequent promoter methylation of CDH1, DAPK, RARB, and HIC1 genes in carcinoma of cervix uteri: its relationship to clinical outcome. Molec Cancer. 2003, 2: 24-10.1186/1476-4598-2-24. 10.1186/1476-4598-2-24CrossRef
134.
Virmani AK, Muller C, Rathi A, Zoechbauer-Mueller S, Mathis M, Gazdar AF: Aberrant methylation during cervical carcinogenesis. Clin Cancer Res. 2001, 7: 584-589.PubMed
135.
Dong SM, Kim HS, Rha SH, Sidransky D: Promoter hypermethylation of multiple genes in carcinoma of the uterine cervix. Clin Cancer Res. 2001, 7: 1982-1986.PubMed
136.
Zambrano P, Segura-Pacheco B, Pérez-Cárdenas E, Cetina L, Revilla-Vázquez A, Taja-Chayeb L, Chávez-Blanco A, Angeles E, Cabrera G, Sandoval K, Trejo-Becerril C, Chanona-Vilchis J, Dueñas-González A: A phase I study of hydralazine to demethylate and reactivate the expression of tumor suppressor genes. BMC Cancer. 2005, 5: 44-10.1186/1471-2407-5-44. 10.1186/1471-2407-5-44PubMedCentralPubMedCrossRef
137.
Uthoff SM, Eichenberger MR, McAuliffe TL, Hamilton CJ, Galandiuk S: Wingless-type frizzled protein receptor signaling and its putative role in human colon cancer. Molec Carcinogen. 2001, 31: 56-62. 10.1002/mc.1039.CrossRef
138.
Hajra KM, Fearon ER: Cadherin and catenin alterations in human cancer. Genes Chromosomes Cancer. 2002, 34: 255-268. 10.1002/gcc.10083.PubMedCrossRef
139.
Persad S, Troussard AA, McPhee TR, Mulholland DJ, Dedhar S: Tumor suppressor PTEN inhibits nuclear accumulation of beta-catenin and T cell/lymphoid enhancer factor 1-mediated transcriptional activation. J Cell Biol. 2001, 153: 1161-1174. 10.1083/jcb.153.6.1161.PubMedCentralPubMedCrossRef
140.
Giles RH, van Es JH, Clevers H: Caught up in a Wnt storm: Wnt signaling in cancer. Biochim Biophys Acta. 2003, 1653: 1-24.PubMed
141.
Thorstensen L, Lind GE, Lovig T, Diep CB, Meling GI, Rognum TO, Lothe RA: Genetic and epigenetic changes of components affecting the WNT pathway in colorectal carcinomas stratified by microsatellite instability. Neoplasia. 2005, 7: 99-108.PubMedCentralPubMedCrossRef
142.
Cheung TH, Lo KW, Yim SF, Chan LK, Heung MS, Chan CS, Cheung AY, Chung TK, Wong YF: Epigenetic and genetic alternation of PTEN in cervical neoplasm. Gynecol Oncol. 2004, 93: 621-627. 10.1016/j.ygyno.2004.03.013.PubMedCrossRef
143.
Widschwendter A, Ivarsson L, Blassnig A, Muller HM, Fiegl H, Wiedemair A, Muller-Holzner E, Goebel G, Marth C, Widschwendter M: CDH1 and CDH13 methylation in serum is an independent prognostic marker in cervical cancer patients. Int J Cancer. 2004, 109: 163-166. 10.1002/ijc.11706.PubMedCrossRef
144.
Kang S, Kim JW, Kang GH, Park NH, Song YS, Kang SB, Lee HP: Polymorphism in folate- and methionine-metabolizing enzyme and aberrant CpG island hypermethylation in uterine cervical cancer. Gynecol Oncol. 2005, 96: 173-180. 10.1016/j.ygyno.2004.09.031.PubMedCrossRef
145.
Chen CL, Liu SS, Ip SM, Wong LC, Ng TY, Ngan HY: E-cadherin expression is silenced by DNA methylation in cervical cancer cell lines and tumours. Eur J Cancer. 2003, 39: 517-523. 10.1016/S0959-8049(02)00175-2.PubMedCrossRef
146.
Muller HM, Widschwendter A, Fiegl H, Goebel G, Wiedemair A, Muller-Holzner E, Marth C, Widschwendter M: A DNA methylation pattern similar to normal tissue is associated with better prognosis in human cervical cancer. Cancer Lett. 2004, 209: 231-236. 10.1016/j.canlet.2003.12.016.PubMedCrossRef
147.
Esteller M, Sparks A, Toyota M, Sánchez-Cespedes M, Capella G, Peinado MA, González S, Tarafa G, Sidransky D, Meltzer SJ, Baylin SB, Herman JG: Analysis of adenomatous polyposis coli promoter hypermethylation in human cancer. Cancer Res. 2000, 60: 4366-4371.PubMed
148.
Zysman M, Saka A, Millar A, Knight J, Chapman W, Bapat B: Methylation of adenomatous polyposis coli in endometrial cancer occurs more frequently in tumors with microsatellite instability phenotype. Cancer Res. 2002, 62: 3663-PubMed
149.
Pegg AE, Byers TL: Repair of DNA containing O6-alkylguanine. FASEB J. 1992, 6: 2302-2310.PubMed
150.
Esteller M, Herman JG: Generating mutations but providing chemosensitivity: the role of O6-methylguanine DNA methyltransferase in human cancer. Oncogene. 2004, 23: 1-8. 10.1038/sj.onc.1207316.PubMedCrossRef
151.
Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, Bromberg JE, Hau P, Mirimanoff RO, Cairncross JG, Janzer RC, Stupp R: MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005, 352: 997-1003. 10.1056/NEJMoa043331.PubMedCrossRef
152.
Park TJ, Han SU, Cho YK, Paik WK, Kim YB, Lim IK: Methylation of O(6)-methylguanine-DNA methyltransferase gene is associated significantly with K-ras mutation, lymph node invasion, tumor staging, and disease free survival in patients with gastric carcinoma. Cancer. 2001, 92: 2760-2768. 10.1002/1097-0142(20011201)92:11<2760::AID-CNCR10123>3.0.CO;2-8.PubMedCrossRef
153.
Qi J, Zhu YQ, Huang MF, Yang D: Hypermethylation of CpG island in O6-methylguanine-DNA methyltransferase gene was associated with K-ras G to A mutation in colorectal tumor. World J Gastroenterol. 2005, 11: 2022-2025.PubMedCentralPubMedCrossRef
154.
Zuo C, Ai L, Ratliff P, Suen JY, Hanna E, Brent TP, Fan CY: O6-methylguanine-DNA methyltransferase gene: epigenetic silencing and prognostic value in head and neck squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev. 2004, 13: 967-975.PubMed
155.
Komine C, Watanabe T, Katayama Y, Yoshino A, Yokoyama T, Fukushima T: Promoter hypermethylation of the DNA repair gene O6-methylguanine-DNA methyltransferase is an independent predictor of shortened progression free survival in patients with low-grade diffuse astrocytomas. Brain Pathol. 2003, 13: 176-184.PubMedCrossRef
156.
Kutler DI, Singh B, Satagopan J: A 20-year perspective on the International Fanconi Anemia Registry (IFAR). Blood. 2003, 101: 1249-1256. 10.1182/blood-2002-07-2170.PubMedCrossRef
157.
Joenje H, Patel KJ: The emerging genetic and molecular basis of Fanconi anaemia. Nature Rev Genet. 2001, 2: 446-457. 10.1038/35076590.PubMedCrossRef
158.
D'Andrea AD, Grompe M: The Fanconi anaemia/BRCA pathway. Nat Rev Cancer. 2003, 3: 23-34. 10.1038/nrc970.PubMedCrossRef
159.
Taniguchi T, Tischkowitz M, Ameziane N: Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors. Nature Med. 2003, 9: 568-574. 10.1038/nm852.PubMedCrossRef
160.
Marsit CJ, Liu M, Nelson HH, Posner M, Suzuki M, Kelsey KT: Inactivation of the Fanconi anemia/BRCA pathway in lung and oral cancers: implications for treatment and survival. Oncogene. 2004, 23: 1000-1004. 10.1038/sj.onc.1207256.PubMedCrossRef
161.
Narayan G, Arias-Pulido H, Nandula SV, Basso K, Sugirtharaj DD, Vargas H, Mansukhani M, Villella J, Meyer L, Schneider A, Gissmann L, Durst M, Pothuri B, Murty VV: Promoter hypermethylation of FANCF: disruption of Fanconi Anemia-BRCA pathway in cervical cancer. Cancer Res. 2004, 64: 2994-2997. 10.1158/0008-5472.CAN-04-0245.PubMedCrossRef
162.
Jass JR: HNPCC and sporadic MSI-H colorectal cancer: a review of the morphological similarities and differences. Fam Cancer. 2004, 3: 93-100. 10.1023/B:FAME.0000039849.86008.b7.PubMedCrossRef
163.
Aaltonen LA, Peltomaki P, Mecklin JP, Jarvinen H, Jass JR, Green JS, Lynch HT, Watson P, Tallqvist G, Juhola M, Sistonen P, Hamilton SR, Kinzler KW, Vogelstein B, de la Chapelle A: Replication errors in benign and malignant tumors from hereditary non-polyposis colorectal cancer patients. Cancer Res. 1994, 54: 1645-1648.PubMed
164.
Deng G, Chen A, Hong J, Chae HS, Kim YS: Methylation of CpG in a small region of the hMLH1 promoter invariably correlates with the absence of gene expression. Cancer Res. 1999, 59: 2029-2033.PubMed
165.
de las Alas MM, Aebi S, Fink D, Howell SB, Los G: Loss of DNA mismatch repair: effects on the rate of mutation to drug resistance. Natl Cancer Inst. 1997, 89: 1537-1541. 10.1093/jnci/89.20.1537.CrossRef
166.
Gifford G, Paul J, Vasey PA, Kaye SB, Brown R: The acquisition of hMLH1 methylation in plasma DNA after chemotherapy predicts poor survival for ovarian cancer patients. Clin Cancer Res. 2004, 10: 4420-4426. 10.1158/1078-0432.CCR-03-0732.PubMedCrossRef
167.
Ciavattini A, Piccioni M, Tranquilli AL, Filosa A, Pieramici T, Goteri G: Immunohistochemical expression of DNA mismatch repair (MMR) system proteins (hMLH1, hMSH2) in cervical preinvasive and invasive lesions. Pathol Res Pract. 2005, 201: 21-25. 10.1016/j.prp.2004.09.012.PubMedCrossRef
168.
Kwasniewska A, Gozdzicka-Jozefiak A, Postawski K, Miturski R: Evaluation of DNA mismatch repair system in cervical dysplasias and invasive carcinomas related to HPV infection. Eur J Gynaecol Oncol. 2002, 23: 231-235.PubMed
169.
Chung TK, Cheung TH, Wang VW, Yu MY, Wong YF: Microsatellite instability, expression of hMSH2 and hMLH1 and HPV infection in cervical cancer and their clinico-pathological association. Gynecol Obstet Invest. 2001, 52: 98-103. 10.1159/000052951.PubMedCrossRef
170.
Ercoli A, Ferrandina G, Genuardi M, Zannoni GF, Cicchillitti L, Raspaglio G, Carrara S, Mancuso S, Scambia G: Microsatellite instability is not related to response to cisplatin-based chemotherapy in cervical cancer. Int J Gynecol Cancer. 2005, 15: 308-311. 10.1111/j.1525-1438.2005.15221.x.PubMedCrossRef
171.
Dammann R, Schagdarsurengin U, Seidel C, Strunnikova M, Rastetter M, Baier K, Pfeifer GP: The tumor suppressor RASSF1A in human carcinogenesis: an update. Histol Histopathol. 2005, 20: 645-663.PubMed
172.
Cohen Y, Singer G, Lavie O, Dong SM, Beller U, Sidransky D: The RASSF1A tumor suppressor gene is commonly inactivated in adenocarcinoma of the uterine cervix. Clin Cancer Res. 2003, 9: 2981-2984.PubMed
173.
Kuzmin I, Liu L, Dammann R, Geil L, Stanbridge EJ, Wilczynski SP, Lerman MI, Pfeifer GP: Inactivation of RAS association domain family 1A gene in cervical carcinomas and the role of human papillomavirus infection. Cancer Res. 2003, 63: 1888-1893.PubMed
174.
Yu MY, Tong JH, Chan PK, Lee TL, Chan MW, Chan AW, Lo KW, To KF: Hypermethylation of the tumor suppressor gene RASSFIA and frequent concomitant loss of heterozygosity at 3p21 in cervical cancers. Int J Cancer. 2003, 105: 204-209. 10.1002/ijc.11051.PubMedCrossRef
175.
Deiss LP, Feinstein E, Berissi H, Cohen O, Kimchi A: Identification of a novel serine/threonine kinase and a novel 15-kD protein as potential mediators of the gamma interferon-induced cell death. Genes Dev. 1995, 9: 15-30.PubMedCrossRef
176.
Shohat G, Shani G, Eisenstein M, Kimchi A: The DAP-kinase family of proteins: study of a novel group of calcium-regulated death-promoting kinases. Biochem Biophys Acta. 2002, 1600: 45-50.PubMed
177.
Inbal B, Cohen O, Polak-Charcon S, Kopolovic J, Vadai E, Eisenbach L, Kimchi A: DAP kinase links the control of apoptosis to metastasis. Nature. 1997, 390: 180-184. 10.1038/36599.PubMedCrossRef
178.
Watabe K, Ito A, Koma YI, Kitamura Y: IGSF4: a new intercellular adhesion molecule that is called by three names, TSLC1, SgIGSF and SynCAM, by virtue of its diverse function. Histol Histopathol. 2003, 18: 1321-1329.PubMed
179.
Steenbergen RD, Kramer D, Braakhuis BJ, Stern PL, Verheijen RH, Meijer CJ, Snijders PJ: TSLC1 gene silencing in cervical cancer cell lines and cervical neoplasia. J Natl Cancer Inst. 2004, 96: 294-305.PubMedCrossRef
180.
Li J, Zhang Z, Bidder M, Funk MC, Nguyen L, Goodfellow PJ, Rader JS: IGSF4 promoter methylation and expression silencing in human cervical cancer. Gynecol Oncol. 2005, 96: 150-158. 10.1016/j.ygyno.2004.08.050.PubMedCrossRef
181.
Wistuba II, Montellano FD, Milchgrub S, Virmani AK, Behrens C, Chen H, Ahmadian M, Nowak JA, Muller C, Minna JD, Gazdar AF: Deletions of chromosome 3p are frequent and early events in the pathogenesis of uterine cervical carcinoma. Cancer Res. 1997, 57: 3154-3158.PubMed
182.
Larson AA, Kern S, Curtiss S, Gordon R, Cavenee WK, Hampton GM: High resolution analysis of chromosome 3p alterations in cervical carcinoma. Cancer Res. 1997, 57: 4082-4090.PubMed
183.
Hendricks DT, Taylor R, Reed M, Birrer MJ: FHIT gene expression in human ovarian, endometrial, and cervical cancer cell lines. Cancer Res. 1997, 57: 2112-2115.PubMed
184.
Birrer MJ, Hendricks D, Farley J, Sundborg MJ, Bonome T, Walts MJ, Geradts J: Abnormal Fhit expression in malignant and premalignant lesions of the cervix. Cancer Res. 1999, 59: 5270-5274.PubMed
185.
Connolly DC, Greenspan DL, Wu R, Ren X, Dunn RL, Shah KV, Jones RW, Bosch FX, Muñoz N, Cho KR: Loss of fhit expression in invasive cervical carcinomas and intraepithelial lesions associated with invasive disease. Clin Cancer Res. 2000, 6: 3505-3510.PubMed
186.
Greenspan DL, Connolly DC, Wu R, Lei RY, Vogelstein JT, Kim YT, Mok JE, Muñoz N, Bosch FX, Shah K, Cho KR: Loss of FHIT expression in cervical carcinoma cell lines and primary tumors. Cancer Res. 1997, 57: 4692-4698.PubMed
187.
Nakagawa S, Yoshikawa H, Kimura M, Kawana K, Matsumoto K, Onda T, Kino N, Yamada M, Yasugi T, Taketani Y: A possible involvement of aberrant expression of the FHIT gene in the carcinogenesis of squamous cell carcinoma of the uterine cervix. Br J Cancer. 1999, 79: 589-594. 10.1038/sj.bjc.6690093.PubMedCentralPubMedCrossRef
188.
Yoshino K, Enomoto T, Nakamura T, Sun H, Ozaki K, Nakashima R, Wada H, Saitoh J, Watanabe Y, Noda K, Murata Y: FHIT alterations in cancerous and non-cancerous cervical epithelium. Int J Cancer. 2000, 85: 6-13. 10.1002/(SICI)1097-0215(20000101)85:1<6::AID-IJC2>3.0.CO;2-6.PubMedCrossRef
189.
Roz L, Gramegna M, Ishii H, Croce CM, Sozzi G: Restoration of fragile histidine triad (FHIT) expression induces apoptosis and suppresses tumorigenicity in lung and cervical cancer cell lines. Proc Natl Acad Sci U S A. 2002, 99: 3615-3620. 10.1073/pnas.062030799.PubMedCentralPubMedCrossRef
190.
Wu Q, Shi H, Suo Z, Nesland JM: 5'-CpG island methylation of the FHIT gene is associated with reduced protein expression and higher clinical stage in cervical carcinomas. Ultrastruct Pathol. 2003, 27: 417-422.PubMed
191.
Chen WY, Zeng X, Carter MG, Morrell CN, Chiu Yen RW, Esteller M, Watkins DN, Herman JG, Mankowski JL, Baylin SB: Heterozygous disruption of Hic1 predisposes mice to a gender-dependent spectrum of malignant tumors. Nature Genet. 2003, 33: 197-202. 10.1038/ng1077.PubMedCrossRef
192.
Chen W, Cooper TK, Zahnow CA, Overholtzer M, Zhao Z, Ladanyi M, Karp JE, Gokgoz N, Wunder JS, Andrulis IL, Levine AJ, Mankowski JL, Baylin SB: Epigenetic and genetic loss of Hic1 function accentuates the role of p53 in tumorigenesis. Cancer Cell. 2004, 6: 387-398. 10.1016/j.ccr.2004.08.030.PubMedCrossRef
193.
Chambon P: The retinoid signaling pathway: molecular and genetic analyses. Semin Cell Biol. 1994, 5: 115-125. 10.1006/scel.1994.1015.PubMedCrossRef
194.
Widschwendter M, Berger J, Hermann M, Muller HM, Amberger A, Zeschnigk M, Widschwendter A, Abendstein B, Zeimet AG, Daxenbichler G, Marth C: Methylation and silencing of the retinoic acid receptor-beta2 gene in breast cancer. J Natl Cancer Inst. 2000, 92: 826-832. 10.1093/jnci/92.10.826.PubMedCrossRef
195.
196.
Khan MA, Jenkins GR, Tolleson WH, Creek KE, Pirisi L: Retinoic acid inhibition of human papillomavirus mediated transformation of human keratinocytes. Cancer Res. 1993, 53: 905-909.PubMed
197.
Meyskens FL, Surwit E, Moon TE, Childers JM, Davis JR, Dorr RT, Jonson CS, Alberts DS: Enhancement of regression of cervical intraepithelial neoplasia II (moderate dysplasia) with topically applied all-trans retinoic acid: a randomized trial. J Natl Cancer Inst. 1994, 86: 539-543.PubMedCrossRef
198.
Lippman SM, Kavanagh JJ, Paredes-Espinoza M, Delgadillo-Madrueno F, Paredes Casillas P, Hong WK, Massimini G, Holdener EE, Kazakoff IH: 13-cis-Retinoic acid plus interferon-α2a in locally advanced squamous cell carcinoma of cervix. J Natl Cancer Inst. 1993, 85: 499-500.PubMedCrossRef
199.
Geraddts J, Chen JY, Russell EA, Yankaskas JR, Nieves L, Minna JD: Human cancer cell lines exhibit resistance to retinoic acid treatment. Cell Growth Differ. 1993, 4: 799-809.
200.
Ivanova T, Petrenko A, Gritsko T, Vinokourova S, Eshilev E, Kobzeva V, Kisseljov F, Kisseljova N: Methylation and silencing of the retinoic acid receptor-beta 2 gene in cervical cancer. BMC Cancer. 2002, 2: 4-10.1186/1471-2407-2-4. 10.1186/1471-2407-2-4PubMedCentralPubMedCrossRef
201.
Feng Q, Balasubramanian A, Hawes SE, Toure P, Sow PS, Dem A, Dembele B, Critchlow CW, Xi L, Lu H, McIntosh MW, Young AM, Kiviat NB: Detection of hypermethylated genes in women with and without cervical neoplasia. J Natl Cancer Inst. 2005, 97: 273-282.PubMedCrossRef
202.
Ivanova T, Vinokurova S, Petrenko A, Eshilev E, Solovyova N, Kisseljov F, Kisseljova N: Frequent hypermethylation of 5' flanking region of TIMP-2 gene in cervical cancer. Int J Cancer. 2004, 108: 882-886. 10.1002/ijc.11652.PubMedCrossRef
203.
Widschwendter A, Muller HM, Fiegl H, Ivarsson L, Wiedemair A, Muller-Holzner E, Goebel G, Marth C, Widschwendter M: DNA methylation in serum and tumors of cervical cancer patients. Clin Cancer Res. 2004, 10: 565-571. 10.1158/1078-0432.CCR-0825-03.PubMedCrossRef
204.
Razani B, Altschuler Y, Zhu L, Pestell RG, Mostov KE, Lisanti MP: Caveolin-1 expression is down-regulated in cells transformed by the human papilloma virus in a p53-dependent manner. Replacement of caveolin-1 expression suppresses HPV-mediated cell transformation. Biochemistry. 2000, 39: 13916-13924. 10.1021/bi001489b.PubMedCrossRef
205.
Chan TF, Su TH, Yeh KT, Chang JY, Lin TH, Chen JC, Yuang SS, Chang JG: Mutational, epigenetic and expressional analyses of caveolin-1 gene in cervical cancers. Int J Oncol. 2003, 23: 599-604.PubMed
206.
Kim YI, Giuliano A, Hatch KD, Schneider A, Nour MA, Dallal GE, Selhub J, Mason JB: Global DNA hypomethylation increases progressively in cervical dysplasia and carcinoma. Cancer. 1994, 74: 893-899.PubMedCrossRef
207.
Fowler BM, Giuliano AR, Piyathilake C, Nour M, Hatch K: Hypomethylation in cervical tissue: is there a correlation with folate status?. Cancer Epidemiol Biomarkers Prev. 1998, 7: 901-906.PubMed
208.
de Capoa A, Musolino A, Della Rosa S, Caiafa P, Mariani L, Del Nonno F, Vocaturo A, Donnorso RP, Niveleau A, Grappelli C: DNA demethylation is directly related to tumour progression: evidence in normal, pre-malignant and malignant cells from uterine cervix samples. Oncol Rep. 2003, 10: 545-549.PubMed
209.
Watanabe S, Iwasaka T, Yokoyama M, Uchiyama M, Kaku T, Matsuyama T: Analysis of nuclear chromatin distribution in cervical glandular abnormalities. Acta Cytol. 2004, 48: 505-513.PubMedCrossRef
210.
Bernstein BE, Humphrey EL, Erlich RL, Schneider R, Bouman P, Liu JS, Kouzarides T, Schreiber SL: Methylation of histone H3 Lys 4 in coding regions of active genes. Proc Natl Acad Sci U S A. 2002, 99: 8695-8700. 10.1073/pnas.112318199.PubMedCentralPubMedCrossRef
211.
Fraga MF, Ballestar E, Villar-Garea A, Boix-Chornet M, Espada J, Schotta G, Bonaldi T, Haydon C, Ropero S, Petrie K, Iyer NG, Pérez-Rosado A, Calvo E, López JA, Cano A, Calasanz MJ, Colomer D, Piris MA, Ahn N, Imhof A, Caldas C, Jenuwein T, Esteller M: Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nature Genet. 2005, 37: 391-400. 10.1038/ng1531.PubMedCrossRef
212.
Seligson DB, Horvath S, Shi T, Yu H, Tze S, Grunstein M, Kurdistani SK: Global histone modification patterns predict risk of prostate cancer recurrence. Nature. 2005, 435: 1262-1266. 10.1038/nature03672.PubMedCrossRef
213.
Anton M, Horky M, Kuchtickova S, Vojtesek B, Blaha O: Immunohistochemical detection of acetylation and phosphorylation of histone H3 in cervical smears. Ceska Gynekol. 2004, 69: 3-6.PubMed
214.
Vigushin DM, Coombes RC: Targeted histone deacetylase inhibition for cancer therapy. Curr Cancer Drug Targets. 2004, 4: 205-218. 10.2174/1568009043481560. 10.2174/1568009043481560PubMedCrossRef
215.
Longworth MS, Laimins LA: The binding of histone deacetylases and the integrity of zinc finger-like motifs of the E7 protein are essential for the life cycle of human papillomavirus type 31. Virology. 2004, 78: 3533-3541. 10.1128/JVI.78.7.3533-3541.2004.CrossRef
216.
Brehm A, Nielsen SJ, Miska EA, McCance DJ, Reid JL, Bannister AJ, Kouzarides T: The E7 oncoprotein associates with Mi2 and histone deacetylase activity to promote cell growth. EMBO J. 1999, 18: 2449-2458. 10.1093/emboj/18.9.2449.PubMedCentralPubMedCrossRef
217.
Zimmermann H, Degenkolbe R, Bernard HU, O'Connor MJ: The human papillomavirus type 16 E6 oncoprotein can down-regulate p53 activity by targeting the transcriptional coactivator CBP/p300. J Virol. 1999, 73: 6209-6219.PubMedCentralPubMed
218.
Bernat A, Massimi P, Banks L: Complementation of a p300/CBP defective-binding mutant of adenovirus E1a by human papillomavirus E6 proteins. J Genet Virol. 2002, 83: 829-833.CrossRef
219.
Rainier S: Relaxation of imprinted genes in human cancer. Nature. 1993, 362: 747-749. 10.1038/362747a0.PubMedCrossRef
220.
Ehrlich M: Hypomethylation and hypermethylation of DNA in Wilms tumors. Oncogene. 2002, 21: 6694-6702. 10.1038/sj.onc.1205890.PubMedCrossRef
221.
Brown KW, Williams JC, Maitland NJ, Mott MG: Genomic imprinting and the Beckwith-Wiedemann syndrome. Am J Hum Genet. 1990, 46: 1000-1001.PubMedCentralPubMed
222.
Douc-Rasy S, Barrois M, Fogel S, Ahomadegbe JC, Sthelin D, Coll , Riou G: High incidence of loss of heterozygosity and abnormal imprinting of H19 and IGF2 genes in invasive cervical carcinomas. Uncoupling of H19 and IGF2 expression and biallelic hypomethylation of H19. Oncogene. 1996, 12: 423-430.PubMed
223.
Clarke EA, Anderson TW: Does screening by "Pap" smears help prevent cervical cancer? A case-control study. Lancet. 1979, 2: 1-4. 10.1016/S0140-6736(79)90172-7.PubMedCrossRef
224.
Fahey MT, Irwing L, Macaskill P: Meta-analysis of pap test accuracy. Am J Epidemiol. 1995, 141: 680-689.PubMed
225.
Nieh S, Chen SF, Chu TY, Lai HC, Lin YS, Fu E, Gau CH: Is p16(INK4A) expression more useful than human papillomavirus test to determine the outcome of atypical squamous cells of undetermined significance-categorized Pap smear? A comparative analysis using abnormal cervical smears with follow-up biopsies. Gynecol Oncol. 2005, 97: 35-40. 10.1016/j.ygyno.2004.11.034.PubMedCrossRef
226.
Kalof AN, Evans MF, Simmons-Arnold L, Beatty BG, Cooper K: p16INK4A immunoexpression and HPV in situ hybridization signal patterns: potential markers of high-grade cervical intraepithelial neoplasia. Am J Surg Pathol. 2005, 29: 674-679. 10.1097/01.pas.0000155164.78785.c2.PubMedCrossRef
227.
Feng Q, Balasubramanian A, Hawes SE, Toure P, Sow PS, Dem A, Dembele B, Critchlow CW, Xi L, Lu H, McIntosh MW, Young AM, Kiviat NB: Detection of hypermethylated genes in women with and without cervical neoplasia. Natl Cancer Inst. 2005, 97: 273-282.CrossRef
228.
Stroun M, Anker P, Maurice P, Lyautey J, Lederrey C, Beljanski M: Neoplastic characteristics of the DNA found in the plasma of cancer patients. Oncology. 1989, 46: 318-322.PubMedCrossRef
229.
Sorenson GD, Pribish DM, Valone FH, Memoli VA, Bzik DJ, Yao SL: Soluble normal and mutated DNA sequences from single-copy genes in human blood. Cancer Epidemiol Biomarkers Prev. 1994, 3: 67-71.PubMed
230.
Vasioukhin V, Anker P, Maurice P, Lyautey J, Lederrey C, Stroun M: Point mutations of the N-ras gene in the blood plasma DNA of patients with myelodysplastic syndrome or acute myelogenous leukemia. Br J Haematol. 1994, 86: 774-779.PubMedCrossRef
231.
Anker P, Stroun M: Progress in the knowledge of circulating nucleic acids: plasma RNA is particle-associated. Can it become a general detection marker for a cancer blood test?. Clin Chem. 2002, 48: 1210-1211.PubMed
232.
Trejo-Becerril C, Pérez-Cárdenas E, Treviño-Cuevas H, Taja-Chayeb L, García-López P, Segura-Pacheco B, Chávez-Blanco A, Lizano-Soberón M, González-Fierro A, Mariscal I, Wegman-Ostrosky T, Dueñas-González A: Circulating nucleosomes and response to chemotherapy: an in vitro, in vivo and clinical study on cervical cancer patients. Int J Cancer. 2003, 104: 663-668. 10.1002/ijc.11003.PubMedCrossRef
233.
Herman JG: Circulating methylated DNA. Ann N Y Acad Sci. 2004, 1022: 33-39. 10.1196/annals.1318.006.PubMedCrossRef
234.
Dulaimi E, Uzzo RG, Greenberg RE, Al-Saleem T, Cairns P: Detection of bladder cancer in urine by a tumor suppressor gene hypermethylation panel. Clin Cancer Res. 2004, 10: 1887-1893. 10.1158/1078-0432.CCR-03-0127.PubMedCrossRef
235.
Wang YC, Lu YP, Tseng RC, Lin RK, Chang JW, Chen JT, Shih CM, Chen CY: Inactivation of hMLH1 and hMSH2 by promoter methylation in primary non-small cell lung tumors and matched sputum samples. J Clin Invest. 2003, 111: 887-895. 10.1172/JCI200315475.PubMedCentralPubMedCrossRef
236.
Yang HJ, Liu VW, Wang Y, Chan KY, Tsang PC, Khoo US, Cheung AN, Ngan HY: Detection of hypermethylated genes in tumor and plasma of cervical cancer patients. Gynecol Oncol. 2003, 93: 435-440. 10.1016/j.ygyno.2004.01.039.CrossRef
237.
Jones PA, Taylor SM: Cellular differentiation, cytidine analogs and DNA methylation. Cell. 1980, 20: 85-93. 10.1016/0092-8674(80)90237-8.PubMedCrossRef
238.
Abele R, Clavel M, Dodion P, Bruntsch U, Gundersen S, Smyth J, Renard J, van Glabbeke M, Pinedo HM: The EORTC Early Clinical Trials Cooperative Group experience with 5-aza-2'-deoxycytidine (NSC 127716) in patients with colo-rectal, head and neck, renal carcinomas and malignant melanomas. Eur J Cancer Clin Oncol. 1987, 23: 1921-1924. 10.1016/0277-5379(87)90060-5.PubMedCrossRef
239.
240.
Chan AT, Tao Q, Robertson KD, Flinn IW, Mann RB, Klencke B, Kwan WH, Leung TW, Johnson PJ, Ambinder RF: Azacytidine induces demethylation of the Epstein-Barr virus genome in tumors. J Clin Oncol. 2004, 22: 1373-1381. 10.1200/JCO.2004.04.185.PubMedCrossRef
241.
Goffin J, Eisenhauer E: DNA methyltransferase inhibitors- state of the art. Ann Oncol. 2002, 13: 1699-116. 10.1093/annonc/mdf314.PubMedCrossRef
242.
Beaulieu N, Fournel M, Macleod A: Antitumor activity of MG98, an antisense oligonucleotide targeting DNA methyltransferase-1 (DNMT1). [Abstract]. Clin Cancer Res. 2001, 7: 3800S-
243.
Davis AJ, Moore MJ, Gelmon KA: Phase 1 and pharmacodynamic study of human DNA methyltransferase (MeTase) antisense oligodeoxynucleotide (ODN), MG98, administered as 21-day infusion q4 weekly [Abstract]. Clin Cancer Res. 2000, 6: 4517S-
244.
Segura-Pacheco B, Trejo-Becerril C, Pérez-Cárdenas E, Taja-Chayeb L, Mariscal I, Chávez A, Acuña C, Salazar AM, Lizano M, Dueñas-González A: Reactivation of tumor suppressor genes by the cardiovascular drugs hydralazine and procainamide and their potential use in cancer therapy. Clin Cancer Res. 2003, 9: 1596-603.PubMed
245.
Angeles E, Vázquez-Valadez VH, Vázquez-Valadez O, Velázquez-Sánchez AM, Ramírez A, Martínez L, Díaz-Barriga S, Romero-Rojas A, Cabrera G, López-Castañares R, Dueñas-González A: Computational studies of 1-Hydrazinophtalazine (Hydralazine) as antineoplastic agent. Docking studies on methyltransferase. Lett Drug Design Discov. 2005, 4: 282-286. 10.2174/1570180054038413. 10.2174/1570180054038413CrossRef
246.
Shao Y, Gao Z, Marks PA, Jiang X: Apoptotic and autophagic cell death induced by histone deacetylase inhibitors. Proc Natl Acad Sci U S A. 2004, 101: 18030-18035. 10.1073/pnas.0408345102.PubMedCentralPubMedCrossRef
247.
Knupfer MM, Pulzer F, Schindler I, Hernaiz Driever P, Knupfer H, Keller E: Different effects of valproic acid on proliferation and migration of malignant glioma cells in vitro. Anticancer Res. 2001, 21: 347-351.PubMed
248.
Kim MS, Blake M, Baek JH, Kohlhagen G, Pommier Y, Carrier F: Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA. Cancer Res. 2003, 63: 7291-7300.PubMed
249.
Zhang Y, Jung M, Dritschilo A, Jung M: Enhancement of radiation sensitivity of human squamous carcinoma cells by histone deacetylase inhibitors. Radiat Res. 2004, 161: 667-674.PubMedCrossRef
250.
Drummond DC, Noble CO, Kirpotin DB, Guo Z, Scott GK, Benz CC: Clinical development of histone deacetylase inhibitors as anticancer agents. Annu Rev Pharmacol Toxicol. 2005, 45: 495-528. 10.1146/annurev.pharmtox.45.120403.095825.PubMedCrossRef
251.
Kelly WK, O'Connor OA, Krug LM, Chiao JH, Heaney M, Curley T, MacGregore-Cortelli B, Tong W, Secrist JP, Schwartz L, Richardson S, Chu E, Olgac S, Marks PA, Scher H, Richon VM: Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol. 2005, 23: 3923-3931. 10.1200/JCO.2005.14.167.PubMedCentralPubMedCrossRef
252.
Ryan QC, Headlee D, Acharya M, Sparreboom A, Trepel JB, Ye J, Figg WD, Hwang K, Chung EJ, Murgo A, Melillo G, Elsayed Y, Monga M, Kalnitskiy M, Zwiebel J, Sausville EA: Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma. J Clin Oncol. 2005, 23: 3912-3922. 10.1200/JCO.2005.02.188.PubMedCrossRef
253.
Prakash S, Foster BJ, Meyer M, Wozniak A, Heilbrun LK, Flaherty L, Zalupski M, Radulovic L, Valdivieso M, LoRusso PM: Chronic oral administration of CI-994: a phase 1 study. Invest New Drugs. 2001, 19: 1-11. 10.1023/A:1006489328324.PubMedCrossRef
254.
Reid T, Valone F, Lipera W, Irwin D, Paroly W, Natale R, Sreedharan S, Keer H, Lum B, Scappaticci F, Bhatnagar A: Phase II trial of the histone deacetylase inhibitor pivaloyloxymethyl butyrate (Pivanex, AN-9) in advanced non-small cell lung cancer. Lung Cancer. 2004, 45: 381-386. 10.1016/j.lungcan.2004.03.002.PubMedCrossRef
255.
Shi H, Wei SH, Leu YW, Rahmatpanah F, Liu JC, Yan PS, Nephew KP, Huang TH: Triple analysis of the cancer epigenome: an integrated microarray system for assessing gene expression, DNA methylation, and histone acetylation. Cancer Res. 2003, 63: 2164-2171.PubMed
256.
Cameron EE, Bachman KE, Myohanen S, Herman JG, Baylin SB: Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nature Genet. 1999, 21: 103-107. 10.1038/5047.PubMedCrossRef
257.
Primeau M, Gagnon J, Momparler RL: Synergistic antineoplastic action of DNA methylation inhibitor 5-AZA-2'-deoxycytidine and histone deacetylase inhibitor depsipeptide on human breast carcinoma cells. Int J Cancer. 2003, 103: 177-184. 10.1002/ijc.10789.PubMedCrossRef
258.
Bovenzi V, Momparler RL: Antineoplastic action of 5-aza-2'-deoxycytidine and histone deacetylase inhibitor and their effect on the expression of retinoic acid receptor beta and estrogen receptor alpha genes in breast carcinoma cells. Cancer Chemother Pharmacol. 2001, 48: 71-76. 10.1007/s002800100294.PubMedCrossRef
259.
Keen JC, Yan L, Mack KM, Pettit C, Smith D, Sharma D, Davidson NE: A novel histone deacetylase inhibitor, scriptaid, enhances expression of functional estrogen receptor alpha (ER) in ER negative human breast cancer cells in combination with 5-aza 2'-deoxycytidine. Breast Cancer Res Treat. 2003, 81: 177-186. 10.1023/A:1026146524737.PubMedCrossRef
260.
Zhu WG, Lakshmanan RR, Beal MD, Otterson GA: DNA methyltransferase inhibition enhances apoptosis induced by histone deacetylase inhibitors. Cancer Res. 2001, 61: 1327-1333.PubMed
261.
Vermorken JB, Tumolo S, Roozendaal KJ, Guastalla JP, Splinter TA, Renard J: 5-aza-2'-deoxycytidine in advanced or recurrent cancer of the uterine cervix. Eur J Cancer. 1991, 27: 5216-217.
262.
Nyce JW: Drug-induced DNA hypermethylation: a potential mediator of acquired drug resistance during cancer chemotherapy. Mutat Res. 1997, 386: 153-161. 10.1016/S1383-5742(96)00051-8.PubMedCrossRef
263.
Pohlmann P, DiLeone LP, Cancella AI, Caldas AP, Dal Lago L, Campos O, Monego E, Rivoire W, Schwartsmann G: Phase II trial of cisplatin plus decitabine, a new DNA hypomethylating agent, in patients with advanced squamous cell carcinoma of the cervix. Am J Clin Oncol. 2002, 25: 496-501. 10.1097/00000421-200210000-00015.PubMedCrossRef
264.
Munster PN, Marchion DC, Bicaku E, Sullivan P, Beam C, Mahany J, Lush R, Sullivan DM, Daud A: Phase I trial of the histone deacetylase inhibitor, valproic acid and the topoisomerase II inhibitor, epirubicin: a clinical and translational study [Abstract]. Procc ASCO. 2005, 24:
265.
Chávez-Blanco A, Segura-Pacheco B, Pérez-Cárdenas E, Taja-Chayeb L, Cetina L, Candelaria M, Cantú D, Pérez-Plasencia C, Cabrera G, Trejo-Becerril C, Angeles E, González-Fierro A, García-López P, Zambrano P, Dueñas-González A: Histone acetylation and histone deacetylase activity of magnesium valproate in tumor and peripheral blood of patients with cervical cancer. A phase I study. Molec Cancer. 2005, 4: 22-10.1186/1476-4598-4-22. 10.1186/1476-4598-4-22CrossRef
266.
Forrer C, Hofstetter B, Pruschy M, Ciernik IF: Treatment with demethylating agent 5-Aza-2'-Deoxy-Cytidine (DAC) leads to enhanced sensitivity to ionizing radiation (IR) in colorectal carcinoma [Abstract]. Radiat Oncol. 2004, 73: S1-S497.
267.
Dote H, Cerna D, Burgan WE, Carter DJ, Cerra MA, Hollingshead MG, Camphausen K, Tofilon PJ: Enhancement of in vitro and in vivo tumor cell radiosensitivity by the DNA methylation inhibitor zebularine. Clin Cancer Res. 2005, 11: 4571-4579. 10.1158/1078-0432.CCR-05-0050.PubMedCrossRef
268.
Zhang Y, Jung M, Dritschilo A, Jung M: Enhancement of radiation sensitivity of human squamous carcinoma cells by histone deacetylase inhibitors. Radiat Res. 2004, 161: 667-674.PubMedCrossRef
269.
Camphausen K, Cerna D, Scott T, Sproull M, Burgan WE, Cerra MA, Fine H, Tofilon PJ: Enhancement of in vitro and in vivo tumor cell radiosensitivity by valproic acid. Int J Cancer. 2005, 114: 380-386. 10.1002/ijc.20774.PubMedCrossRef
270.
Chung YL, Wang AJ, Yao LF: Antitumor histone deacetylase inhibitors suppress cutaneous radiation syndrome: implications for increasing therapeutic gain in cancer radiotherapy. Molec Cancer Ther. 2004, 3: 317-325.CrossRef
Metadata
Title
Epigenetics of cervical cancer. An overview and therapeutic perspectives
Authors
Alfonso Dueñas-González
Marcela Lizano
Myrna Candelaria
Lucely Cetina
Claudia Arce
Eduardo Cervera
Publication date
01-12-2005
Publisher
BioMed Central
Published in
Molecular Cancer / Issue 1/2005
Electronic ISSN: 1476-4598
DOI
https://doi.org/10.1186/1476-4598-4-38

Other articles of this Issue 1/2005

Molecular Cancer 1/2005 Go to the issue

Short communication

Inactivation of MAP kinase signalling in Myc Transformed Cells and Rescue by LiCl inhibition of GSK3

Research

C/EBPbeta-2 confers EGF-independent growth and disrupts the normal acinar architecture of human mammary epithelial cells

Research

Mapping and characterization of the amplicon near APOA2 in 1q23 in human sarcomas by FISH and array CGH

Research

Global gene expression in neuroendocrine tumors from patients with the MEN1 syndrome

Research

Survivin 2α: a novel Survivin splice variant expressed in human malignancies

Research

Heat shock protein 72 expression allows permissive replication of oncolytic adenovirus dl1520 (ONYX-015) in rat glioblastoma cells
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits